Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17184380 | 0.88 | NAMPT (0.62) | NAMPTMAPTALDH1A1SMN1; SMN2CD274 | |
| SCHEMBL17184394 | 0.80 | MAPT (0.61) | NAMPTMAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL28128764 | 0.79 | SLC2A1 (0.54) | NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL28129294 | 0.77 | NAMPT (0.49) | NAMPTALDH1A1LMNA | |
| SCHEMBL12100260 | 0.77 | MTOR (0.50) | NAMPTMAPT | |
| SCHEMBL12076644 | 0.77 | MTOR (0.50) | NAMPTMAPT | |
| SCHEMBL17184460 | 0.76 | NAMPT (1.00) | NAMPT | |
| SCHEMBL12100243 | 0.76 | MAPT (0.44) | NAMPTMAPTLMNASMN1; SMN2 | |
| SCHEMBL12099824 | 0.76 | NAMPT (0.58) | NAMPTMAPT | |
| SCHEMBL12100636 | 0.76 | NAMPT (0.56) | NAMPTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144742-B2 | Quinoxaline compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3131881-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015161142-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144742-B2 | Quinoxaline compounds and uses thereof | NAMPT, NQO2, NNMT | NAMPT 1/4885MAPT 2452/4885ALDH1A1 1374/4885 |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | NAMPT 1/4885MAPT 2452/4885ALDH1A1 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.